The biotech sector has been hit hard in 2014, with many of the biggest names in the industry taking falls. Three top companies, Alnylam Pharmaceuticals (NASDAQ:ALNY), Theravance (NASDAQ:THRX), and Amgen (NASDAQ:AMGN), are all down year to date. But are these tumbling biotech stocks great opportunities for investors in search of rebound candidates in 2014?

Alnylam has made progress on its RNA interference program, and the company has reported upbeat clinical data lately. Theravance has increasingly pushed into the growing COPD market in recent years. Amgen, one of the largest biotechs on the market, took an earnings-related hit in April, but there could be an opportunity for savvy investors at its valuation.

So why is the market down on these stocks? Find out in the video below, as Motley Fool contributor Dan Carroll takes you through what's behind these three slipping picks and whether they can mount comebacks over the next few months.

Don't be left behind in the next wave of health-care innovation
The Economist compares this disruptive invention to the steam engine and the printing press. Business Insider says it's "the next trillion dollar industry." And the technology behind is poised to set off one of the most remarkable health care revolutions in decades. The Motley Fool's exclusive research presentation dives into this technology's true potential, and its ability to make life-changing medical solutions never thought possible. To learn how you can invest in this unbelievable new technology, click here now to see our free report.

Dan Carroll has no position in any stocks mentioned. The Motley Fool recommends Alnylam Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Compare Brokers